FR13C0012I1 - - Google Patents

Info

Publication number
FR13C0012I1
FR13C0012I1 FR13C0012C FR13C0012I1 FR 13C0012 I1 FR13C0012 I1 FR 13C0012I1 FR 13C0012 C FR13C0012 C FR 13C0012C FR 13C0012 I1 FR13C0012 I1 FR 13C0012I1
Authority
FR
France
Prior art keywords
ciprofloxacin
treatment
disclosed
aqueous suspension
formulations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23261416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0012(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0012I1 publication Critical patent/FR13C0012I1/fr
Application granted granted Critical
Publication of FR13C0012I2 publication Critical patent/FR13C0012I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR13C0012C 2001-09-21 2013-02-21 Procede de traitement de l'infection de l'oreille moyenne Active FR13C0012I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32395101P 2001-09-21 2001-09-21
PCT/US2002/029373 WO2003026671A1 (en) 2001-09-21 2002-09-13 Method of treating middle ear infections

Publications (2)

Publication Number Publication Date
FR13C0012I1 true FR13C0012I1 (ja) 2013-04-05
FR13C0012I2 FR13C0012I2 (fr) 2014-02-14

Family

ID=23261416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0012C Active FR13C0012I2 (fr) 2001-09-21 2013-02-21 Procede de traitement de l'infection de l'oreille moyenne

Country Status (19)

Country Link
US (8) US20030139382A1 (ja)
EP (1) EP1429780B1 (ja)
JP (1) JP2005504804A (ja)
KR (1) KR20040035760A (ja)
CN (1) CN1231218C (ja)
AT (1) ATE313328T1 (ja)
AU (1) AU2002333671B2 (ja)
BR (1) BR0212898A (ja)
CA (1) CA2459930C (ja)
CY (1) CY1104988T1 (ja)
DE (1) DE60208216T2 (ja)
DK (1) DK1429780T3 (ja)
ES (1) ES2250739T3 (ja)
FR (1) FR13C0012I2 (ja)
MX (1) MXPA04002576A (ja)
PL (1) PL212457B1 (ja)
RU (1) RU2295346C2 (ja)
WO (1) WO2003026671A1 (ja)
ZA (1) ZA200401847B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002576A (es) * 2001-09-21 2004-06-18 Alcon Inc Metodo para tratar infecciones del oido medio.
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
PE20060489A1 (es) * 2004-08-13 2006-06-19 Schering Plough Ltd Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
AU2009246870B2 (en) * 2008-05-14 2013-08-01 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
WO2009152374A2 (en) 2008-06-12 2009-12-17 Medtronic Xomed, Inc. Method for treating chronic wounds
CN102112112A (zh) * 2008-07-21 2011-06-29 奥德纳米有限公司 用于治疗耳部病症的受控释放抗微生物组合物和方法
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100086576A1 (en) * 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
CA2753837A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
EP2440165A4 (en) * 2009-06-08 2014-01-22 Otic Pharma Ltd FOAM FORMULATIONS FOR THE EAR
EP2490722A4 (en) * 2009-10-21 2014-03-05 Otonomy Inc MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS
WO2012154953A2 (en) 2011-05-10 2012-11-15 Microbial Defense Systems, Llc Antimicrobial solid and methods of making and using same
WO2014102788A1 (en) * 2012-12-26 2014-07-03 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
MX2016002408A (es) * 2013-08-27 2016-10-28 Otonomy Inc Metodos para el tratamiento de trastornos oticos pediatricos.
US20150119371A1 (en) * 2013-10-30 2015-04-30 Micro Labs Limited Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents
KR20170021353A (ko) * 2014-07-03 2017-02-27 오토노미, 인코포레이티드 시프로플록사신 조성물의 멸균
US9393243B1 (en) * 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
US11040004B2 (en) 2016-09-16 2021-06-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134718A (en) * 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US5223493A (en) * 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
AU4201189A (en) * 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
DK0604570T3 (da) * 1991-09-17 1998-09-14 Alcon Lab Inc Præparater, der indeholder quinolon-antibiotika og sulfonat af polystyren
ES2065846B1 (es) 1993-04-20 1995-10-01 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
ES2078175B1 (es) 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
ATE214931T1 (de) 1995-06-06 2002-04-15 Bayer Ag Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
BR9914158A (pt) 1998-09-30 2001-06-26 Alcon Lab Inc Composição antibiótica para o tratamento dos olhos, ouvidos e nariz
TR200200737T2 (tr) * 1999-09-24 2002-08-21 Alcon, Inc. Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
MXPA04002576A (es) * 2001-09-21 2004-06-18 Alcon Inc Metodo para tratar infecciones del oido medio.

Also Published As

Publication number Publication date
AU2002333671B2 (en) 2006-07-20
PL212457B1 (pl) 2012-10-31
US9149486B2 (en) 2015-10-06
US9345714B2 (en) 2016-05-24
ES2250739T3 (es) 2006-04-16
KR20040035760A (ko) 2004-04-29
EP1429780A1 (en) 2004-06-23
BR0212898A (pt) 2004-10-13
EP1429780B1 (en) 2005-12-21
US20080214513A1 (en) 2008-09-04
FR13C0012I2 (fr) 2014-02-14
CA2459930C (en) 2009-11-10
WO2003026671A1 (en) 2003-04-03
CN1231218C (zh) 2005-12-14
US20150374716A1 (en) 2015-12-31
CA2459930A1 (en) 2003-04-03
US20140363511A1 (en) 2014-12-11
JP2005504804A (ja) 2005-02-17
US20160361324A1 (en) 2016-12-15
US20090156566A1 (en) 2009-06-18
MXPA04002576A (es) 2004-06-18
ATE313328T1 (de) 2006-01-15
US9402805B1 (en) 2016-08-02
US20030139382A1 (en) 2003-07-24
CN1555267A (zh) 2004-12-15
RU2004111984A (ru) 2005-02-27
DE60208216T2 (de) 2006-06-29
CY1104988T1 (el) 2009-11-04
RU2295346C2 (ru) 2007-03-20
US20160243029A1 (en) 2016-08-25
US8846650B2 (en) 2014-09-30
US20050059674A1 (en) 2005-03-17
DE60208216D1 (de) 2006-01-26
ZA200401847B (en) 2005-05-25
DK1429780T3 (da) 2006-02-13
PL369205A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
FR13C0012I1 (ja)
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
AU2386201A (en) Substituted sapogenins and their use
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
AU2002305400A1 (en) Medical device and methods of use for glaucoma treatment
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
IL145795A0 (en) Mutant human cd80 and compositions for and methods of making and using the same
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
GB9923078D0 (en) Sapogenin derivatives and their use
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU5842300A (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
CZ20012085A3 (cs) Použití riluzolu při léčení sluchových poruch
WO2000027376A3 (de) Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus
AU7626800A (en) Middle-ear implant
UA36410A (uk) Спосіб аудіометричного обстеження слухової системи людини
AU2001255056A1 (en) Vaccine for the treatment of tubercolosis and other intracellular infections diseases
AU1007401A (en) Treatment of respiratory diseases and infections
AUPR916701A0 (en) Composition for the treatment of infectious and/or skin diseases
AU2002315231A1 (en) Method and apparatus for obtaining geometrical data relating to the ear canal of the human body
AUPR171000A0 (en) Composition for the treatment of infectious and/or skin diseases
AU2001265906A1 (en) Chemical alteration of mammal urine and mammal blood